Dashboard
Manage Tickers

ABVX Abivax S.A.

Nasdaq www.abivax.com


$ 102.59 $ 0.44 (0.43 %)    

Thursday, 06-Nov-2025 09:54:34 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 618.75 $ -3.04 (-0.49 %)
DIA $ 471.00 $ -1.02 (-0.22 %)
SPY $ 674.97 $ -1.51 (-0.22 %)
TLT $ 89.63 $ 0.07 (0.08 %)
GLD $ 367.33 $ 0.38 (0.1 %)
$ 99.61
$ 102.84
$ 102.43 x 5
$ 102.75 x 100
$ 102.13 - $ 103.57
$ 4.77 - $ 108.00
713,486
na
6.28B
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-brinker-international-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Brinker International Analyst Begins ...
11/06/2025 13:34:52

wolfe-research-initiates-coverage-on-abivax-with-outperform-rating-announces-price-target-of-176
Wolfe Research Initiates Coverage On Abiva...
11/06/2025 13:22:54

Wolfe Research analyst Steve Fleishman initiates coverage on Abivax (NASDAQ:ABVX) with a Outperform rating and announces Pri...

Core News & Articles
Abivax Data From Phase 3 ABTECT 8-Week Ind...
11/03/2025 21:16:53

Abivax SA (Euronext PARIS:FR0012333284 – ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage bio...

barclays-initiates-coverage-on-abivax-with-overweight-rating-announces-price-target-of-142
Barclays Initiates Coverage On Abivax with...
10/13/2025 11:58:56

Barclays analyst Etzer Darout initiates coverage on Abivax (NASDAQ:ABVX) with a Overweight rating and announces Price Target...

guggenheim-maintains-buy-on-abivax-raises-price-target-to-150
Guggenheim Maintains Buy on Abivax, Raises...
10/10/2025 12:36:10

Guggenheim analyst Yatin Suneja maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $101 to $150.

tilray-brands-posts-upbeat-results-joins-byrna-technologies-delta-air-lines-and-other-big-stocks-moving-higher-on-thursday
Tilray Brands Posts Upbeat Results, Joins ...
10/09/2025 14:14:52

amd-to-rally-more-than-47-here-are-10-top-analyst-forecasts-for-tuesday
AMD To Rally More Than 47%? Here Are 10 To...
10/07/2025 12:13:15

btig-maintains-buy-on-abivax-raises-price-target-to-120
BTIG Maintains Buy on Abivax, Raises Price...
10/07/2025 09:56:29

BTIG analyst Julian Harrison maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $112 to $120.

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/06/2025 17:35:26

why-is-abivax-stock-trading-higher-on-monday
Why Is Abivax Stock Trading Higher On Monday?
10/06/2025 15:05:40

Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no ne...

Core News & Articles
Abivax Drug Obefazimod Shows Results In Ph...
10/06/2025 08:07:24

Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused o...

reported-sunday-abivax-announces-late-breaking-phase-3-data-showing-obefazimod-achieved-164-placebo-adjusted-remission-rate-at-week-8-in-ulcerative-colitis
Reported Sunday, Abivax Announces Late-Bre...
10/06/2025 06:32:05

50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met...

Core News & Articles
Abivax SA Will Present Second Late-breakin...
09/29/2025 20:10:13

Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLIT...

jmp-securities-maintains-market-outperform-on-abivax-raises-price-target-to-114
JMP Securities Maintains Market Outperform...
09/25/2025 13:06:37

JMP Securities analyst Jason N. Butler maintains Abivax (NASDAQ: ABVX) with a Market Outperform and raises the price target ...

Core News & Articles
AbivaxTo Present Late-Breaking Abstract f...
09/23/2025 20:09:36

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United ...

morgan-stanley-maintains-overweight-on-abivax-raises-price-target-to-101
Morgan Stanley Maintains Overweight on Abi...
09/12/2025 15:37:21

Morgan Stanley analyst Judah Frommer maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $71 t...

rh-posts-downbeat-results-joins-frequency-electronics-tronox-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
RH Posts Downbeat Results, Joins Frequency...
09/12/2025 12:24:19

btig-reiterates-buy-on-abivax-maintains-112-price-target
BTIG Reiterates Buy on Abivax, Maintains $...
09/09/2025 11:15:54

BTIG analyst Julian Harrison reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $112 price target.

Core News & Articles
Earnings Scheduled For August 11, 2025
08/11/2025 08:32:28

earnings-outlook-for-abivax
Earnings Outlook For Abivax
08/08/2025 15:01:14

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION